Navigation Links
XTL Biopharmaceuticals Signs $108 Million Deal for the Licensing of its Pre- Clinical Program in Hepatitis C to Presidio Pharmaceuticals
Date:3/20/2008

cal trials, two of which, atazanavir for HIV, and entecavir for Hepatitis B, are currently approved drugs."

Ron Bentsur, XTL's CEO commented: "We are excited about this licensing transaction with a motivated and capable partner such as Presidio. This transaction allows us to solidify our financial position by bringing in $4 million dollars in cash and eliminating the ongoing development expense of the Program, while preserving a significant share in the Program's future success. We believe that this transaction extends our financial resources well into Q1 2009, and provides us with a financial cushion as we head towards the completion and announcement of results from the Bicifadine Phase 2b study, expected in Q4 2008."

The Program focuses on the development of novel small molecule inhibitors against the Hepatitis C virus, and is presently in advanced stages of lead optimization. The current lead compounds target NS5A - a viral protein that is essential for viral production. NS5A is distinct from the protease and polymerase. The Program's lead compounds are highly potent inhibitors of viral replication in the replicon assay, which is known to have good correlation with clinical efficacy and is currently the leading method for preclinical testing of inhibitors of the Hepatitis C Virus.

ABOUT XTL BIOPHARMACEUTICALS LTD.

XTL Biopharmaceuticals Ltd. ("XTL") is engaged in the development of therapeutics for the treatment of diabetic neuropathic pain and HCV. XTL is developing Bicifadine, a serotonin and norepinephrine reuptake inhibitor, for the treatment of diabetic neuropathic pain, which is currently in a Phase 2b study. XTL has out-licensed its novel pre-clinical HCV small molecule inhibitor program. XTL also has an active in-licensing and acquisition program designed to identify and acquire additional drug candidates. XTL is publicly traded on the NASDAQ and Tel-Aviv Stock Exchanges (NASDAQ:

SOURCE XTL Biopharmaceuticals Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
2. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
3. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
4. XTL Biopharmaceuticals Announces Presentation of Novel Pre-Clinical Inhibitors of Hepatitis C at an Upcoming International Scientific Conference
5. XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
6. Nabi Biopharmaceuticals Announces Sale of Nabi Biologics to Biotest AG
7. Keryx Biopharmaceuticals to Present at Bank of America Investment Conference
8. Morria Biopharmaceuticals Plc Announces Appointment of Dr. Rosemary Mazanet as Interim Chief Executive Officer
9. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
10. Morria Biopharmaceuticals Plc Appoints Dr. Johnson Lau and Dr. David Sidransky to Board of Directors
11. XTL Biopharmaceuticals Ltd. AGM / EGM Postponed Until October 2, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... , May 26, 2015 Pharmaco-Kinesis Corporation (PKC) ... recently convened at Shutters on the Beach in ... development status of the Company,s innovative Metronomic Biofeedback Pump ... locally deliver chemotherapy over time to a target site ... capacity and biofeedback system in real-time.  ...
(Date:5/26/2015)... Kevin Xu , prezident MEBO ... Obamovi a Billovi Clintonovi za ich kondolencie a ... Rongxiang Xu , otca Kevina. ... Xu bol pionier, inovátor, humanitárny pracovník a vodca ... vedy a príkladné vedenie svojej komunity zanecháva odkaz, ...
(Date:5/26/2015)... , May 26, 2015  Asterias Biotherapeutics, Inc. ... emerging field of regenerative medicine, today announced that all ... 2014 were exercised prior to their expiry on June ... of $11.7 million. "We thank our shareholders ... President and CEO of Asterias. "This exercise of warrants ...
(Date:5/26/2015)... 26, 2015 /PRNewswire/ - Fluorinov Pharma (Fluorinov), a FACIT ... M. Beshar to its Board of Directors.  His ... industry expertise as Fluorinov accelerates its clinical development activities.  ... it is a pleasure to welcome Luke to the ... on the strategy, financial strength and success of multiple ...
Breaking Biology Technology:Pharmaco-Kinesis Corporation Convenes Third Neuro-Oncology Clinical Advisory Board Meeting 2Pharmaco-Kinesis Corporation Convenes Third Neuro-Oncology Clinical Advisory Board Meeting 3Pharmaco-Kinesis Corporation Convenes Third Neuro-Oncology Clinical Advisory Board Meeting 4Pharmaco-Kinesis Corporation Convenes Third Neuro-Oncology Clinical Advisory Board Meeting 5Dr. Rongxiang Xu, O legende 2Asterias Biotherapeutics Receives $11.7 Million in Proceeds from Exercise of Warrants 2Asterias Biotherapeutics Receives $11.7 Million in Proceeds from Exercise of Warrants 3Luke M. Beshar Appointed to Fluorinov Pharma Board of Directors 2Luke M. Beshar Appointed to Fluorinov Pharma Board of Directors 3
... ABC,s Dancing with the Stars champion Drew Lachey has teamed ... launch the first national online video contest to increase ... The contest invites people to ... that help them stay active and healthy., ...
... EXTON, Pa., May 6 BioTrends Research Group,Inc. ... comprehensive insight into the management of,renal anemia and ... and Dialysis. These reports provide information from 105 ... -- data were collected,through an online survey fielded ...
... May 6 MedImmune today announced that,it ... the company,s expanded product,pipeline in the United ... core scientific,research that underpins this development. Jacqueline ... development team leadership; Lorin,Roskos, Ph.D. has been ...
Cached Biology Technology:Dancing With the Stars' Drew Lachey and Novo Nordisk Launch Dancin' to Change Diabetes National Video Contest 2BioTrends Releases Two Publications - TreatmentTrends(TM): Nephrologists and TreatmentTrends(TM): Renal Dietitians - Highlighting Market Trends for Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism 2BioTrends Releases Two Publications - TreatmentTrends(TM): Nephrologists and TreatmentTrends(TM): Renal Dietitians - Highlighting Market Trends for Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism 3MedImmune Fortifies Strategic Scientific Portfolio Management and International Leadership With New Executive Appointments 2MedImmune Fortifies Strategic Scientific Portfolio Management and International Leadership With New Executive Appointments 3
(Date:4/20/2015)... The announcement comes as demand for fire vault ... Ireland,s foremost records management company, has secured ... impressive track record of clients within the first 12 months, ... sector in Dubai . As a result, ... a further eight staff members at its Irish headquarters. The ...
(Date:4/14/2015)... , April 14, 2015  HYPR Corp. ... Online (FIDO ® ) Alliance tm , an ... FIDO members commit to share technology and collaborate ... that are interoperable, more secure and private, and ... biometric identity verification that protects sensitive user information ...
(Date:4/13/2015)... 13, 2015 According to ... Biometrics Market Forecast & Opportunities, 2020", the global biometrics ... around 14% till 2020. The biometrics market is ... implementation and review of biometric management systems. The ... products with greater efficiency, are resulting in increasing ...
Breaking Biology News(10 mins):Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2
... Researchers from the Intermountain Medical Center Heart Institute, ... the National Institutes of Health, have discovered a simple ... heart disease: by measuring their body mass index or ... study is part of a larger study called faCTor-64, ...
... line of defense against viruses, bacteria and parasites that might ... a systematic chain of molecular signaling launches to close the ... study led by researchers from the University of Pennsylvania,s School ... role of one of the players in the wound-healing process, ...
... first comprehensive multi-model-based assessment of so-called Durban Platform scenarios, ... the Potsdam Institute for Climate Impact Research (PIK) and ... Durban Platform is the current negotiation track at the ... climate agreement by 2015 to come into effect in ...
Cached Biology News:Body mass index may predict heart disease risk for type-2 diabetic patients new study finds 2Body mass index may predict heart disease risk for type-2 diabetic patients new study finds 3Penn Dental Medicine team identifies molecule critical to healing wounds 2Success of climate talks vital for 2°C target 2Success of climate talks vital for 2°C target 3
... Benzonase Nuclease is a genetically engineered endonuclease. ... DNA and RNA while having no proteolytic ... range of conditions and possesses an exceptionally ... nucleic acids from recombinant proteins, its use ...
...
... Microarrays designed for genome-wide microRNA ... flexible and powerful Paraflo microfluidic on-chip ... as part of our comprehensive microRNA ... Content The Fishes microRNA Microarray ...
...
Biology Products: